$XBI $89.59 | -1.96%
Covid Updates
$MRNA +1.6% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant source
$IBIO -4.2% iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease. source
$NRXP -3.8% NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge. source
Pipeline Updates
$CUE +8.3% Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer source
$XBIT -2.2% XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ. source
$AKTX +5.3% Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases. source
$VCNX +8.8% Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer. source
$CYCN -2.4% Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology. source
$HEPA -2.5% Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study. source
$CRTX -31.5% Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application. source
$ALGS -2.4% Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401). source
$EVAX -9.3% Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck. source
$IMCR +7.5% Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma. source
$TYME -37.5% TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer. source
$MNOV MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe. source
Business Updates
$ZYME +3.5% Zymeworks Announces Proposed Public Offering source
$EPZM -5.5% Epizyme Announces Proposed Public Offering of Common Stock source
$EOLS +17.3% Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance. source
$MYOV -0.4% Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates. source
Posted by FS/JM
Comments